米国市場銘柄情報

XERS ゼリスファーマシューティカルズ

銘柄追加

1.895
+0.005+0.26%

終値 05/06 16:00 ET

1.949
+0.054+2.82%

市場前 08:00 ET

2.81億時価総額-4211直近PER

ゼリスファーマシューティカルズに関するコメント

ログインコメントを投稿

Trytosaveabit

昨日 19:03

Update

$ゼリスファーマシューティカルズ(XERS.US)$ Reuters· 1 min ago
Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems

Moomoo AI

03/02 22:00

Despite Xeris Biopharma Holdings' strong performance, its growth projections are subdued compared to the industry. This could lead to a share price decline if the P/S ratio falls to align with the growth outlook.

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 29% But Its Business Is Yet to Catch Up

SpyderCall

01/10 21:56

Making Moves in Premarket.

$ゼリスファーマシューティカルズ(XERS.US)$

Sturgeons and Stocks

01/10 21:42

$ゼリスファーマシューティカルズ(XERS.US)$

Trytosaveabit

01/10 21:05

News

$ゼリスファーマシューティカルズ(XERS.US)$Moomoo 24/7· 1 min ago1min
Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones

Moomoo AI

01/06 03:44

Xeris Biopharma's poor revenue growth forecast and subpar industry growth dampen optimism around the stock’s future. Despite a share price surge, market sentiment remains pessimistic and strong future increases appear unlikely.

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Bounce 32% But Its Business Still Trails The Industry

Trytosaveabit

2023/10/17 00:47

$ゼリスファーマシューティカルズ(XERS.US)$ I guess tweaks to company can help? hehehe! Company Tightened FY23 Revenue Guidance and Raised 2023 Cash, Cash Equivalents and Short-term Investment Guidance